Related Experiment Video

Updated: Dec 26, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.9K

A perspective on targeting inflammation and cytokine actions in atherosclerosis

Yee-Hung Chan1, Dipak P Ramji1

  • 1Cardiff School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3AX, UK.

Future Medicinal Chemistry
|March 17, 2020
PubMed

Insights

Targeting inflammation, specifically interleukin-1 beta (IL-1β), shows promise in treating atherosclerosis and reducing cardiovascular disease. Recent trials highlight this approach, with ongoing research into future therapeutic strategies.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Pharmacology

Background:

  • Atherosclerosis is a major cause of cardiovascular disease, driven by chronic vascular inflammation.
  • Interleukin-1 beta (IL-1β) is a key pro-inflammatory cytokine implicated in atherosclerosis progression.
  • Targeting inflammation is a recognized therapeutic strategy for cardiovascular conditions.

Purpose of the Study:

  • To provide a perspective on targeting vascular inflammation in atherosclerosis.
  • To review recent Phase III clinical trial results for anti-inflammatory therapies.
  • To discuss future challenges and prospects in atherosclerosis treatment.

Main Methods:

  • Review of recent Phase III clinical trial data.
  • Analysis of the role of IL-1β in atherosclerosis.
  • Discussion of emerging anti-inflammatory therapeutic candidates.

Main Results:

  • The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated successful outcomes by inhibiting IL-1β.
  • Targeting IL-1β offers a viable strategy for managing atherosclerosis.
  • Several other anti-inflammatory targets are under investigation.

Conclusions:

  • Inhibition of IL-1β represents a significant advancement in atherosclerosis treatment.
  • Future research should focus on novel anti-inflammatory targets and personalized medicine approaches.
  • Addressing the inflammatory component of atherosclerosis holds promise for reducing cardiovascular events.

Keywords:
IL-1βatherosclerosiscardiovascular diseasecytokinesinflammation

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.7K
Flow Cytometry Analysis of Immune Cells Within Murine Aortas15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

35.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
272
Inflammation01:38

Inflammation

Overview
61.2K
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.7K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
684
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
389
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K